Rapport surges as bipolar mania drug succeeds mid-stage trial
BUZZ-Rapport surges as bipolar mania drug succeeds mid-stage trial ** Shares of Rapport Therapeutics RAPP.O rise 54.7% to $44 premarket
** Co says its bipolar mania treatment, RAP-219, met the main goal and secondary goals in a mid-stage trial
** Mania is a distinct period of abnormally elevated, irritable or euphoric mood accompanied by a severe spike in energy, activity and racing thoughts lasting at least one week
** RAPP says patients who took the treatment had a 15.4-point mean reduction in the total score on the Young Mania Rating Scale (YMRS), which measures and quantifies the severity of manic symptoms
** Co says all 11 items measured by the YMRS improved numerically compared to placebo at week 3, with improvements in irritability and disruptive-aggressive behavior reaching nominal significance
** Stock down 5.7% YTD, as of last close
(Reporting by Christy Santhosh)